報價延遲最少15分鐘:2026/04/03 14:49 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
564.81 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
27.86/35.23
|
|
企業價值
25.29B
|
| 資產負債 |
|
每股賬面淨值
161.91
|
| 現金流量 |
|
現金流量率
0.06
|
| 損益表 |
|
收益
3.18B
|
|
每股收益
50.29
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United Statesand Rest of the World, of which United States generates majority of the revenue. |
